GlassScriptPhysician profile
Neel Trivedi
NPI 1467870113
$12,705.99
in general payments reported to CMS, 2019-2025
32 companies · $2,920 in 2025
The $2,920 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $98.10 · 2022: $35.87 · 2023: $8,007 · 2024: $1,061 · 2025: $2,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,365 · Food and Beverage: $2,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,365.00 |
| Food and Beverage | $2,622.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $6,677.08 | 2022-2024 | Gazyva, Columvi, Venclexta |
| Taiho Oncology, INC. | $2,800.00 | 2025 | |
| Incyte Corporation | $483.63 | 2019-2024 | Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $354.47 | 2023-2024 | Enhertu, Tagrisso, Imfinzi |
| Genentech, INC. | $299.98 | 2023-2024 | Tecentriq, Alecensa |
| E.R. Squibb & Sons, L.L.C. | $236.71 | 2023 | Reblozyl |
| Tempus Ai, INC | $207.46 | 2024 | Xt Cdx |
| Celgene Corporation | $188.19 | 2019-2024 | Reblozyl |
| Astellas Pharma US INC | $188.00 | 2023-2024 | Xtandi, Xospata |
| Gilead Sciences, INC. | $154.49 | 2023 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $149.52 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $123.17 | 2019 | |
| Genzyme Corporation | $120.14 | 2025 | |
| Jazz Pharmaceuticals INC. | $116.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.10 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $86.53 | 2023-2024 | |
| Daiichi Sankyo INC. | $56.03 | 2023-2024 | Enhertu |
| Myriad Genetic Laboratories, INC. | $49.54 | 2023-2024 | Myrisk |
| Merck Sharp & Dohme LLC | $44.58 | 2024 | Keytruda, Lynparza |
| Foundation Medicine, INC. | $27.51 | 2023 | |
| Sumitomo Pharma America, INC. | $26.81 | 2023 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $24.94 | 2024 | Libtayo |
| Servier Pharmaceuticals LLC | $24.87 | 2024 | |
| Seagen INC. | $23.85 | 2023 | Adcetris |
| Glaxosmithkline, LLC. | $22.87 | 2024 | Jemperli, Zejula |
| Apellis Pharmaceuticals, INC. | $20.96 | 2024 | Empaveli |
| Mirati Therapeutics, INC. | $20.42 | 2023 | Krazati |
| Recordati_rare_diseases_inc. | $17.16 | 2024 | Panhematin |
| Abbvie INC. | $17.00 | 2023 | Venclexta |
| Deciphera Pharmaceuticals INC. | $16.10 | 2024 | Qinlock |
| Adaptive Biotechnologies Corporation | $15.74 | 2024 | Clonoseq |
| Blueprint Medicines Corporation | $13.54 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neel Trivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.